ENO2 and lung cancer: But it still had a great advantage compared to other traditional serum-based biomarkers, such as the sensitivities for lung cancer of CEA, Cyfra21-1, SCC and NSE were 46.2%, 40.0%, 43.1%, and 46.2%, respectively.